PLOS is a non-profit organization on a mission to drive open science forward with measurable, meaningful change in research publishing, policy, and practice.

Building on a strong legacy of pioneering innovation, PLOS continues to be a catalyst, reimagining models to meet open science principles, removing barriers and promoting inclusion in knowledge creation and sharing, and publishing research outputs that enable everyone to learn from, reuse and build upon scientific knowledge.

We believe in a better future where science is open to all, for all.

Journals
More Content
PLOS BLOGS Speaking of Medicine and Health
Browse all PLOS Blogs
Browse all PLOS Blogs

This week in PLoS Medicine: Six-gene predictor in pancreatic cancer treatment; Reviews for devices; Evidence-based policy in Africa

PLOS Medicine General

Image credit: George Gastin

Three new articles were published this week in PLoS Medicine: Jen Jen Yeh and colleagues developed and validated a six-gene signature in patients with pancreatic ductal adenocarcinoma that may be used to better stage the disease in these patients and assist in treatment decisions.

Using examples from recent FDA regulatory proceedings, Jonas Hines and colleagues critique the medical device premarket review and identify eight weaknesses in the process that should be remedied.

Lastly, as part of our continuing series on maternal, neonatal, and child health in sub-Saharan Africa, Igor Rudan and colleagues discuss various priority-setting tools for health care and research that can help develop evidence-based policy. See the earlier blog about the series with all articles which lists all the articles as they are published.

Remember you can comment on, annotate and rate any PLoS Medicine article and see the views, citations and other indications of impact of an article on that articles metrics tab.

Back to top